HOLX News and Press, Hologic Inc. From 11/02/21

Minerva Surgical aims to transform uterine healthcare with its minimally invasive procedures. I like the potential of the business, and despite the current growth, I wonder if the competitive strength of the solutions is strong enough. Given these dynamics, and despite modest sale...

With a 20-Year Legacy, the NovaSure System is the Most Trusted in Global Endometrial Ablation to Address Abnormal Uterine Bleeding (AUB) Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, will launch the NovaSure® V5 global endometrial ablation (GEA) d...

Hologic, Inc. (HOLX) Q4 2021 Earnings Conference Call November 01, 2021, 04:30 PM ET Company Participants Michael Watts - VP of IR and Corporate Communications Stephen MacMillan - Chairman, President and CEO Karleen Oberton - CFO Conference Call Participants Brian Weinstein - William Blair Vi...

Image source: The Motley Fool. Hologic, inc (NASDAQ: HOLX) Q4 2021 Earnings Call Nov 1, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Hologic, inc (HOLX) Q4 2021 Earnings Call Transcript

Although Hologic (NASDAQ:HOLX) reported fiscal year 2021 Q4 revenue and EPS that was considerably lower than in the prior-year period, it was enough to beat Street expectations. Revenue of ~1.32B was ~2.3% lower than in FQ4 2020. While total diagnostics revenues declined 11% to $836.8M, total...

Hologic (NASDAQ:HOLX): FQ4 Non-GAAP EPS of $1.61 beats by $0.60; GAAP EPS of $1.28 beats by $0.57. Revenue of $1.32B (-2.2% Y/Y) beats by $280M. Press Release Guidance FY22: “We expect strong financial results in fiscal 2022, with solid growth in our core women’s health bus...

– Revenue of $1.317 Billion Exceeds Expectations – – Company Posts GAAP Diluted EPS of $1.28, Non-GAAP Diluted EPS of $1.61 – – Financial Guidance for Fiscal 2022 Anticipates Solid Growth in Core Women’s Health Businesses and Continued C...

Hologic (NASDAQ:HOLX) is scheduled to announce FQ4 earnings results on Monday, November 1st, after market close. The consensus EPS Estimate is $1.00 (-51.7% Y/Y) and the consensus Revenue Estimate is $1.04B (-23.0% Y/Y). Hologic saw its Q3 2021 net income jump 95% to $268.4M ($1.04 per d...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

- Aptima® SARS-CoV-2/Flu Assay Tests Simultaneously for SARS-CoV-2, Influenza A and B on Fully Automated Panther® Molecular Diagnostics System - Hologic, Inc. (Nasdaq: HOLX) announced today that its Aptima ® SARS-CoV-2/Flu Assay is now available for the si...